We observed that MTHFD2 expression level is associated with the tumor microenvironment (TME) in BLCA and has the ability to precisely predict the molecular subtypes, inflamed TME, and immunotherapy response in bladder urothelial carcinoma. This evidence concerns the gene MTHFD2 and bladder transitional cell carcinoma.